Aspects of particle science and regulation in pharmaceutical inhalation drug products

Lee M. Nagao, Svetlana Lyapustina, Melinda K. Munos, Mary Devlin Capizzi

Research output: Contribution to journalArticlepeer-review


Pharmaceutical orally inhaled drug products such as metered dose inhalers (MDIs) and dry powder inhalers (DPIs) are used by millions of individuals worldwide to treat symptoms of asthma and chronic obstructive pulmonary disease (e.g., chronic bronchitis, emphysema). Other applications of these products are being developed including inhalation delivery of insulin and medication to treat pain and the symptoms of cystic fibrosis. Analysis and control of particulate matter are important aspects of the development of these drug products. This includes the development and control of particles of drugs delivered to the patient and the characterization and control of foreign particles that may contaminate the final product. The chemistry and manufacture of these products historically have been strictly regulated by the United States Food and Drug Administration (FDA), with many challenging regulatory requirements applied to analysis and control of particles. This paper provides an overview of some of the main areas of particle analysis in inhalation drug products and the current regulatory challenges pertinent to these areas.

Original languageEnglish (US)
Pages (from-to)2261-2267
Number of pages7
JournalCrystal Growth and Design
Issue number6
StatePublished - Nov 1 2005
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics

Fingerprint Dive into the research topics of 'Aspects of particle science and regulation in pharmaceutical inhalation drug products'. Together they form a unique fingerprint.

Cite this